DSIP vs Epithalon

DSIP

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from rabbit cerebral venous blood during induced sleep by Schoenenberger and Monnier in 1977. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep patterns through interactions with multiple neurotransmitter systems, including GABAergic, glutamatergic, and opioidergic pathways. It also influences hypothalamic-pituitary axis regulation, affecting cortisol and growth hormone secretion patterns. Studies published in Peptides demonstrated that DSIP use normalized disturbed sleep patterns in animal models of chronic stress without producing the sedation or rebound effects associated with classical hypnotic agents. Research by Graf and Kastin (1986) in Neuroscience & Biobehavioral Reviews characterized DSIP's ability to cross the blood-brain barrier and its unusually long biological half-life relative to other neuropeptides. Additional investigations have indicated stress-protective effects, with DSIP reducing corticotropin levels and modulating the hypothalamic stress response. Unlike pharmaceutical sleep aids such as benzodiazepines or Z-drugs, DSIP does not directly suppress CNS activity. Instead, research suggests it normalizes sleep architecture, making it of interest for studying physiological rather than pharmacological sleep regulation. Compared to melatonin, DSIP operates through fundamentally different mechanisms, targeting delta wave promotion rather than circadian rhythm entrainment. Store lyophilized DSIP at -20°C, protected from light and moisture. Reconstitute with bacteriostatic water and refrigerate at 2-8°C, using within 4 weeks. DSIP is studied by sleep researchers, neuroendocrinologists, and stress physiologists investigating non-pharmacological approaches to sleep architecture restoration.

Epithalon

Epithalon (also known as Epitalon or epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. Its primary mechanism of action involves activation of telomerase, the enzyme responsible for adding telomeric repeats (TTAGGG) to chromosome ends, thereby counteracting the progressive telomere shortening associated with cellular aging. Published research by Khavinson and colleagues (Bulletin of Experimental Biology and Medicine, 2003) demonstrated that epithalon increased telomerase activity in human somatic cells and extended the replicative lifespan of fibroblast cultures beyond the Hayflick limit. In animal studies, chronic epithalon use in aging rats was associated with increased lifespan and restoration of melatonin secretion rhythms from the pineal gland, which naturally declines with age (Anisimov et al., Mechanisms of Ageing and Development, 2003). The peptide also appears to modulate expression of genes involved in antioxidant defense and circadian rhythm regulation. Compared to other telomerase activators such as TA-65 (a small molecule derived from astragalus), epithalon is a direct peptide bioregulator with a well-characterized tetrapeptide sequence. Research also suggests potential effects on retinal health, with studies indicating photoreceptor preservation in aging retinal models. Store lyophilized powder at -20C protected from moisture; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 21 days. Epithalon is studied by gerontology research centers, telomere biology laboratories, and chronobiology departments investigating age-related decline in pineal gland function.

Frequently Asked Questions